The clinical pharmacokinetics of famciclovir

Clinical Pharmacokinetics

Volumn 31, Issue 1, 1996, Pages 1-8

  Gill, Kanwar S ^a   Wood, Martin J ^a  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CIMETIDINE; DIGOXIN; FAMCICLOVIR; NUCLEOSIDE ANALOG; PENCICLOVIR; PRODRUG; THEOPHYLLINE;

AGED; AREA UNDER THE CURVE; CLINICAL TRIAL; DIET RESTRICTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TRANSFORMATION; DRUG URINE LEVEL; HEMODIALYSIS; HERPES; HERPES ZOSTER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; LIVER DYSFUNCTION; MALE; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; REVIEW;

EID: 0029993960     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199631010-00001     Document Type: Review

References (25)

1. de Miranda P, Blum MR. Pharmacokinetics of acyclovir after intravenous and oral administration. J Antimicrob Chemother 1983; 12 Suppl. B: 29-37
2. Vere Hodge RA. Famciclovir and penciclovir: the mode of action of famciclovir including its conversion to penciclovir. Antivir Chem Chemother 1993; 4: 67-84
3. McMeekin JR, Fowles SE, Winton CF, et al. Rapid high-performance liquid chromatographic method for the analysis of the active antiherpes agent, penciclovir and its precursor. BRL 43259, in human plasma and urine following administration of the oral prodrug, famciclovir. Analytical Proc 1992; 29: 178-80
4. Clarke SE, Harrell AW, Chenery RJ. Role of aldehyde oxidase in the in vitro conversion of famciclovir to penciclovir in human liver. Drug Metab Dispos 1995; 23: 251-4
5. Winton CF, Fowles SE, Vere Hodge RA, et al. Assay of famciclovir and its metabolites, including the antiherpes agent penciclovir,in plasma and urine of rat, dog and man. In: Reid E, Wilson ID, editors. Analysis of drugs and metabolites. Cambridge (UK): Royal Society of Chemistry, 1990: 163-71
6. Pue MA, Pratt SK, Fairless AJ, et al. Linear pharmacokinetics of penciclovir following administration of single oral doses of famciclovir 125, 250, 500 and 750 mg to healthy volunteers. J Antimicrob Chemother 1994; 33: 119-27
7. Pratt SK, Fairless AJ, Pue MA, et al. The absolute bioavailability of the antiviral compound, penciclovir, following a single oral administration of 500mg famciclovir [abstract B118]. Programme and abstracts of the 3rd Congress of the European Academy of Dermatology and Venereology; 1993 Sep 26-30: Copenhagen
8. Fowles SE, Pierce DM, Prince WT, et al. Effect of food on the bioavailability and pharmacokinetics of penciclovir, a novel antiherpes agent, following oral administration of the prodrug, famciclovir. Br J Clin Pharmacol 1990; 29: 620P-21P
9. Fowles SE, Fairless AJ, Pierce DM, et al. A further study of the effect of food on the bioavailability and pharmacokinetics of penciclovir after oral administration of famciclovir. Br J Clin Pharmacol 1991; 32: 657P
10. Pue MA, Benet LZ. Pharmacokinetics of famciclovir in man. Antivir Chem Chemother 1993; 4 Suppl. 1: 47-55
11. Fowles SE, Pierce DM, Prince WT, et al. The tolerance to and pharmacokinetics of penciclovir (BRL 39, 123A), a novel antiherpes agent, administered by intravenous infusion to healthy subjects. Eur J Clin Pharmacol 1992; 43: 513-6
12. Vere Hodge RA, Cheng Y-C. The mode of action of penciclovir. Antivir Chem Chemother 1993; 4 Suppl. 1: 13-24
13. Earnshaw DL, Bacon TH, Darlison SJ, et al. Mode of action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus. Antimicrob Agents Chemother 1992; 36: 2742-57
14. Boyd MR, Safrin S, Kerne R. Penciclovir: a review of its spectrum of activity, selective and cross-resistant pattern. Antivir Chem Chemother 1993; 4 Suppl. 1: 3-11
15. Bacon TH. Moving forward: research and development of a novel antiviral agent. Res Clin Forums 1995; 17 (3): 35-44
16. Boike SC, Pue MA, Freed MI, et al. Pharmacokinetics of famciclovir in subjects with varying degrees of renal impairment. Clin Pharmacol Ther 1994; 55: 418-26
17. Filer CW, Allen GD, Brown TA, et al. Metabolic and pharmacokinetic studies following oral administration of 14C-famciclovir to healthy subjects. Xenobiotica 1994; 24: 357-68
18. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41
19. Pratt SK, Fairless AJ, Pue MA, et al. The haemodialysis of penciclovir [abstract 1286]. Abstracts of 6th International Congress for Infectious Diseases; 1994 Apr 26-30; Prague
20. Pue MA, Boike SC, Freed MI, et al. Pharmacokinetics of penciclovir in subjects with hepatic insufficiency following oral famciclovir. Br J Clin Pharmacol 1944; 37: 494P
21. Fowles SE, Pue MA, Pierce D, et al. Pharmacokinetics of penciclovir in healthy elderly subjects following a single oral administration of 750 mg famciclovir. Br J Clin Pharmacol 1992; 35: 450P
22. Gross G, Wood M, Siederer SK, et al. Penciclovir pharmacokinetics in patients with uncomplicated herpes zoster following oral administration of 250 mg famciclovir [abstract 856]. Abstracts of 7th European Congress of Clinical Microbiology and Infectious Diseases; 1995 Mar 26-30; Vienna. 166-7
23. Pratt SK, Beerahee M, Pue MA, et al. The pharmacokinetics of penciclovir following oral administration of 500mg famciclovir to patients with uncomplicated herpes zoster infection [abstract B119]. Programme and abstracts of the 3rd Congress of the European Academy of Dermatology and Venereology; 1993 Sep 26-30; Copenhagen
24. Daniels S, Schentag JJ. Drug interaction studies and safety of famciclovir in healthy volunteers: a review. Antivir Chem Chemother 1993; 4 Suppl. 1: 57-64
25. Siederer S, Scott S, Rousseau F, et al. Pharmacokinetics of penciclovir following co-administration of famciclovir with zidovudine to HIV positive patients [abstract 855]. Abstracts of 7th European Congress of Clinical Microbiology and Infections Diseases; 1995 Mar 26-30: Vienna. 166